UNSPSC 51101602: Eflornithine

This classification denotes an ornithine decarboxylase inhibitor with the molecular formula C6H12F2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZQN1G5V6SR, chemically known as 2,5-diamino-2-(difluoromethyl)pentanoic acid but generally known as eflornithine, which bears US NIH Compound Identifier 3009. European Medicines Agency schedules Eflornithine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06468MIG.

UNSPSC 51101602 Eflornithine is a Commodity code nominally for a single pharmaceutical product, but the recent state and local opportunities tagged under it show minimal alignment with that scope. The opportunities instead reflect procurement of naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, medical and first aid supplies for emergency response, and pharmacy benefit program services — a misalignment that suggests either broad mis-tagging of healthcare procurement opportunities or the code's application to a wider pharmaceutical and medical supplies category than the narrow product name alone indicates. State and local healthcare agencies, health departments, cooperative purchasing alliances, and municipal fire departments are the primary issuing bodies pursuing work under this code. Activity is geographically dispersed across Florida, Texas, Minnesota and Oregon, and additional states participating in cooperative purchasing vehicles.

Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (due July 26, 2023) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems through competitive bid; the City of Tampa's IFB 26P00145 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000, designated as a sheltered market exclusively for certified Small Local Business Enterprises with a 5% SLBE bid discount; the Texas Health and Human Services Commission's RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional PBM and GPO relationships; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities. The code shows moderate recent activity but poor semantic alignment with its nominal product scope.